retatrutide clinical study trials retatrutide safety The Effect of on Kidney Parameters in Participants With Type 2 Retatrutide for weight loss: – New Phase 3 retatrutide data

In addition, GLP-1 RAs have been identified as an important drug class for not only glucose-lowering but also in reducing cardiovascular disease (CVD) events in adults with T2DM and high atherosclerotic cardiovascular disease (ASCVD) risk.1 GLP-1 RAs stimulate glucose-dependent insulin release in the gut after food intake and inhibit glucagon release with concomitant decreased gastric emptying and low risk of hypoglycemia

This is crucial for individuals with prediabetes or type 2 diabetes

doi: 10.1002/edm2.163 64

Front Cell Dev Biol

For GLP-1 users already experiencing digestive sensitivity, choosing the appropriate form matters